- Home
- PNNT vs CTNM Comparison
PNNT vs CTNM Comparison
Compare PNNT & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNNT
- CTNM
- Stock Information
- Founded
- PNNT 2007
- CTNM 2009
- Country
- PNNT United States
- CTNM United States
- Employees
- PNNT N/A
- CTNM N/A
- Industry
- PNNT Finance: Consumer Services
- CTNM
- Sector
- PNNT Finance
- CTNM
- Exchange
- PNNT Nasdaq
- CTNM Nasdaq
- Market Cap
- PNNT 452.5M
- CTNM 378.7M
- IPO Year
- PNNT 2007
- CTNM 2024
- Fundamental
- Price
- PNNT $6.95
- CTNM $13.50
- Analyst Decision
- PNNT Hold
- CTNM Strong Buy
- Analyst Count
- PNNT 2
- CTNM 4
- Target Price
- PNNT $6.00
- CTNM $29.25
- AVG Volume (30 Days)
- PNNT 567.5K
- CTNM 134.3K
- Earning Date
- PNNT 02-05-2025
- CTNM 02-16-2025
- Dividend Yield
- PNNT 13.09%
- CTNM N/A
- EPS Growth
- PNNT N/A
- CTNM N/A
- EPS
- PNNT 0.75
- CTNM N/A
- Revenue
- PNNT $143,818,000.00
- CTNM N/A
- Revenue This Year
- PNNT N/A
- CTNM N/A
- Revenue Next Year
- PNNT N/A
- CTNM N/A
- P/E Ratio
- PNNT $9.28
- CTNM N/A
- Revenue Growth
- PNNT N/A
- CTNM N/A
- 52 Week Low
- PNNT $6.43
- CTNM $12.33
- 52 Week High
- PNNT $8.04
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- PNNT 54.12
- CTNM N/A
- Support Level
- PNNT $6.73
- CTNM N/A
- Resistance Level
- PNNT $6.98
- CTNM N/A
- Average True Range (ATR)
- PNNT 0.11
- CTNM 0.00
- MACD
- PNNT 0.01
- CTNM 0.00
- Stochastic Oscillator
- PNNT 83.33
- CTNM 0.00
About PNNT PennantPark Investment Corporation
Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.